New study tests taking migraine pill at earliest warning signs

NCT ID NCT07310290

Recruiting now Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking ubrogepant (a migraine medication) during the earliest phase of a migraine—called the prodrome—can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will take it as usual and report their symptoms over 13 weeks. The goal is to see if early treatment can stop a migraine attack before it fully develops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Chicago Headache Center & Research Inst /ID# 272345
RECRUITING

Naperville, Illinois, 60563, United States
Neurology and Pain Specialty Center /ID# 278508
RECRUITING

Aliso Viejo, California, 92656, United States
Tri City Research Center, LLC /ID# 278800
RECRUITING

Grand Island, Nebraska, 68803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.